Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma

Cancer Biology and Therapy

Volumn 5, Issue 1, 2006, Pages 48-53

  Adusumilli, Prasad S ^a   Chan, Mei Ki ^a   Yun, Shin Chun ^a   Hezel, Michael ^a   Chou, Ting Chao ^a   Rusch, Valerie W ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Combination therapy; Gene therapy; HSV

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN; LACTATE DEHYDROGENASE; NV 1066; ONCOLYTIC VIRUS; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS ONCOLYSATE;

ARTICLE; CELL KILLING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ASSAY; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; INFECTION; MALIGNANT NEOPLASTIC DISEASE; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; UPREGULATION; VIRAL GENE THERAPY; VIRUS CULTURE; VIRUS PARTICLE; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 32544450163     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.1.2237     Document Type: Article

References (34)

1. Flores RM. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: The Memorial Sloan-Kettering experience. Lung Cancer 2005; 49:S71-4.
2. Connelly RR, Spirtas R, Myers MH, Percy CL, Fraumeni Jr JF. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987; 78:1053-60.
3. Walker AM, Loughlin JE, Friedlander ER, Rothman KJ, Dreyer NA. Projections of asbestos-related disease 1980-2009. J Occup Med 1983; 25:409-25.
4. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: Past results and recent developments. Lung Cancer 2004; 45:S103-19.
5. Planting AS, Schellens JH, Goey SH, van der Burg ME, de Boer-Dennert M, Stoter G, Verweij, J. Weekly high-dose cisplatin in malignant pleural mesothelioma. Annals of Oncology 1994; 5:373-4.
6. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treatment Reports 1985; 69:711-2.
7. Rusch V, Saltz L, Venkatraman E, Ginsberg R, McCormack P, Burt M, Markman M, Kelsen D. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12:1156-63.
8. Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Therapy 2002; 9:935-45.
9. Delman KA, Zager JS, Bennett JJ, Malhotra S, Ebright MI, McAuliffe PF, Halterman MW, Federoff HJ, Fong Y. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Annals Of Surgery 2002; 236:337-42.
10. Wong RJ, Chan MK, Yu Z, Ghossein RA, Ngai I, Adusumilli PS, Stiles BM, Shan JP, Singh B, Fong Y. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clinical Cancer Research 2004; 10:4509-16.
11. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, Rizk NP, Molnar-Kimber KL, Brown SM, MacLean AR, Litzky LA, Fraser NW, Albelda SM, Kaiser LR. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Research 1997; 57:466-71.
12. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Human Gene Therapy 2002; 13:1213-23.
13. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proceedings of the National Academy of Sciences of the United States of America 1992; 89:3266-70.
14. Chou J, Roizman B. Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proceedings of the National Academy of Sciences of the United States of America 1994; 91:5247-51.
15. Hollander MC, Zhan Q, Bae I, Fornace Jr AJ. Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. Journal Of Biological Chemistry 1997; 272:13731-7.
16. Advani SJ, Chung SM, Yan SY, Gillespie GY, Markert JM, Whitley RJ, Roizman B, Weichselbaum RR. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999; 59:2055-8.
17. Bennett JJ, Adusumilli P, Petrowsky H, Burt BM, Roberts G, Delman KA, Zager JS, Chou TC, Fong Y. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 2004; 18:1001-3.
18. Mullerad M, Bochner BH, Adusumilli PS, Bhargava A, Kikuchi E, Hui-Ni C, Kattan MW, Chou TC, Fong Y. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. Journal Of Urology 2005; 174:741-6.
19. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TCR, ed. Synergism and antagonism in chemotherapy. New York: Academic Press, 1991:61-102.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984; 22:27-55.
21. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. European Journal of Biochemistry 1981; 115:207-16.
22. Chou J, Chou T. Dose-effect analysis with microcomputers: Quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. Manual and Software. Cambridge, UK: Biosoft, 1987.
23. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffle P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-44.
24. Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: A review. Cancer Chemotherapy and Pharmacology 1991; 28:319-30.
25. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncology Reports 2003; 10:1663-82.
26. Stanziale SF, Petrowsky H, Adusumilli PS, Ben Porat L, Gonen M, Fong Y. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: A potential target to increase anticancer activity. Clinical Cancer Research 2004; 10:3225-32.
27. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79.
28. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9:967-78.
29. He B, Chou J, Liebermann DA, Hoffman B, Roizman B. The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. Journal of Virology 1996; 70:84-90.
30. Mullen JT, Kasuya H, Yoon SS, Carroll NM, Pawlik TM, Chandrasekhar S, Nakamura H, Donahue JM, Tanabe KK. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Annals Of Surgery 2002; 236:502-12.
31. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53- independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000; 6:3342-53.
32. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1:162-9.
33. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human nonsmall cell lung cancer. Hum Gene Ther 1999; 10:3013-29.
34. Snyder MB, Saravolatz LD, Markowitz N, Pohlod D, Taylor RC, Ward SG. The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections. Journal of Antimicrobial Chemotherapy 1987; 19:815-22.